Join
Live feed
·
PRReleasevia Quantisnow
Immunomedics, Inc. logo

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

ByQuantisnow·Wall Street's wire, on your screen.
IMMU· Immunomedics, Inc.
Health Care
Full content unavailable. See the original source below.
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMMU (Immunomedics, Inc.) and more on Quantisnow.